Enlitic delivered its strongest quarter yet with A$5.1 million in contracts, including significant agreements with Penn Medicine, St. Jude Children’s Research Hospital, and Parkland Health, while improving cash flow and advancing its AI-powered Ensight platform.
- Record A$5.1m contract value in Q1 FY26
- Major US healthcare wins with Penn Medicine, St. Jude, Parkland Health
- 17 new client agreements signed with higher average values
- Cost reductions to deliver US$2.5m annualised savings
- Completed A$5.4m convertible notes tranche, ending quarter with US$3m cash
Record Contract Wins Drive Growth Momentum
Enlitic, Inc. (ASX:ENL) has smashed its previous quarterly record with A$5.1 million in total contract value for Q1 FY26, reflecting a surge in enterprise and OEM-related deals. This milestone underscores the company’s growing foothold in the US healthcare sector, powered by key agreements with Penn Medicine, St. Jude Children’s Research Hospital, and Parkland Health. The US$1.5 million deal with Penn Medicine marks a second migration project for the University of Pennsylvania Health System affiliate, while the US$250,000 contract with St. Jude signals Enlitic’s inaugural entry into the paediatric healthcare market. The US$1.2 million Parkland Health contract, secured after a competitive tender, includes around 9 million imaging studies with potential expansion to 13 million, integrating Enlitic’s AI-driven Ensight platform early in the migration process. This integrated approach highlights the company’s dual commercial strategy: generating near-term project revenue while laying the groundwork for recurring, higher-margin Software-AI-as-a-Service (SaiS) income through Ensight deployments.
Enlitic signed 17 new client agreements in the quarter, slightly up from 16 in Q4 FY25, but with notably higher average contract sizes. The shift towards larger enterprise and OEM deals aligns with the company’s strategy to deepen relationships with major healthcare institutions and global OEM partners, now totaling eight active engagements. This progress builds on the company’s recent $1.2m Parkland Health contract and the $250K St. Jude contract, both announced earlier in the quarter, reinforcing a strong sales pipeline.
Revenue Timing and Cash Flow Improvements
Despite the record contract wins, revenue for Q1 remained steady at US$0.8 million, unchanged from the prior quarter. This flat performance reflects extended delivery schedules on several major projects, including a broadened scope with a key global healthcare customer, which has delayed revenue recognition but increased overall contract value. Enlitic expects the substantial components of these contracts to contribute to higher revenue in upcoming quarters as project milestones are met. Trade receivables of approximately US$2.5 million at quarter-end provide clear near-term cash conversion visibility, with collections anticipated in Q2 FY26.
Operational cash outflow improved 12% to US$2.9 million from US$3.3 million in Q4 FY25, driven by disciplined cost management and accelerating contract execution. The company implemented cost reduction measures in January 2026, targeting around US$2.5 million in annualised savings, which are expected to flow through fully in Q2. Operating expenses fell from US$3.8 million to US$3.3 million quarter-on-quarter, with marketing spend notably reduced due to the absence of RSNA exhibition costs. Staff costs declined by 4.8%, while research and development expenditure remained steady at US$0.99 million.
Capital Position and Financial Outlook
Enlitic strengthened its balance sheet by completing the second tranche of a convertible notes capital raise, securing A$5.4 million and ending the quarter with US$3.0 million in cash. This funding boost enhances financial flexibility as the company focuses on converting its expanding pipeline into revenue and scaling Ensight deployments. CEO Michael Sistenich emphasised the company’s commitment to operational efficiency and commercial execution, stating that the migration contracts not only generate immediate revenues but also open pathways to recurring SaiS income.
The company’s OEM partnerships, including a binding memorandum of understanding with GE Healthcare, remain a critical component of its forward pipeline, supporting anticipated revenue growth and progress toward operational cashflow break-even. Enlitic has not lost or cancelled any customer contracts during the quarter, reinforcing stability amid its expansion.
Bottom Line?
Enlitic’s record contracts and disciplined cost cuts position it for revenue growth and potential cashflow breakeven, but execution on project delivery and Ensight deployment will be crucial to sustain momentum.
Questions in the middle?
- How quickly will extended delivery schedules translate into recognised revenue in coming quarters?
- Can Enlitic convert its growing installed base into significant recurring SaiS revenue?
- What impact will OEM partnerships, particularly with GE Healthcare, have on long-term growth?